Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Jun;10(11):647.
doi: 10.21037/atm-22-813.

Sacituzumab govitecan in triple-negative breast cancer

Alexandre de Nonneville  1   2 , Anthony Goncalves  1   2 , Emilie Mamessier  1 , François Bertucci  1   2
Affiliations
Editorial

Sacituzumab govitecan in triple-negative breast cancer

Alexandre de Nonneville et al. Ann Transl Med. 2022 Jun.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://atm.amegroups.com/article/view/10.21037/atm-22-813/coif). FB is supported by Institut Paoli-Calmettes, la Ligue Nationale Contre le Cancer (Label Ligue EL2022) and Le Prix Ruban Rose 2020. The other authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
TROP2 gene expression across all tumor samples and paired normal tissues. Each dot represents expression in the clinical samples (tumor in red, normal in green). TCGA cancer type abbreviations (top) are in red when TROP2 is higher in the tumor than in paired normal tissues, in green when lower, in black when no difference was observed (one-way ANOVA, using disease state (tumor or normal) as variable for calculating differential expression. Log2FC cutoff was set at 1 and q-value at 0.01). ACC, adrenocortical carcinoma; BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, cholangiocarcinoma; COAD, colon adenocarcinoma; DLBC, lymphoid neoplasm diffuse large B-cell lymphoma; ESCA, esophageal carcinoma; GBM, glioblastoma multiforme; HNSC, head and neck squamous cell carcinoma; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LAML, acute myeloid leukemia; LGG, brain lower grade glioma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; MESO, mesothelioma; OV, ovarian serous cystadenocarcinoma; PAAD, pancreatic adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; PRAD, prostate adenocarcinoma; READ, rectum adenocarcinoma; SARC, sarcoma; SKCM, skin cutaneous melanoma; STAD, stomach adenocarcinoma; TGCT, testicular germ cell tumors; THCA, thyroid carcinoma; THYM, thymoma; UCEC, uterine corpus endometrial carcinoma; UCS, uterine carcinosarcoma; UVM, uveal melanoma; TCGA, The Cancer Genome Atlas Program; ANOVA, analysis of variance.
See this image and copyright information in PMC

Comment on

  • Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.
    Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Sardesai SD, Kalinsky K, Zelnak AB, Weaver R, Traina T, Dalenc F, Aftimos P, Lynce F, Diab S, Cortés J, O'Shaughnessy J, Diéras V, Ferrario C, Schmid P, Carey LA, Gianni L, Piccart MJ, Loibl S, Goldenberg DM, Hong Q, Olivo MS, Itri LM, Rugo HS; ASCENT Clinical Trial Investigators. Bardia A, et al. N Engl J Med. 2021 Apr 22;384(16):1529-1541. doi: 10.1056/NEJMoa2028485. N Engl J Med. 2021. PMID: 33882206 Clinical Trial.

References

    1. Bertucci F, Finetti P, Birnbaum D. Basal breast cancer: a complex and deadly molecular subtype. Curr Mol Med 2012;12:96-110. 10.2174/156652412798376134 - DOI - PMC - PubMed
    1. Cubas R, Zhang S, Li M, et al. Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway. Mol Cancer 2010;9:253. 10.1186/1476-4598-9-253 - DOI - PMC - PubMed
    1. Guerra E, Trerotola M, Dell' Arciprete R, et al. A bicistronic CYCLIN D1-TROP2 mRNA chimera demonstrates a novel oncogenic mechanism in human cancer. Cancer Res 2008;68:8113-21. 10.1158/0008-5472.CAN-07-6135 - DOI - PubMed
    1. Wang J, Day R, Dong Y, et al. Identification of Trop-2 as an oncogene and an attractive therapeutic target in colon cancers. Mol Cancer Ther 2008;7:280-5. 10.1158/1535-7163.MCT-07-2003 - DOI - PubMed
    1. Bardia A, Mayer IA, Vahdat LT, et al. Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer. N Engl J Med 2019;380:741-51. 10.1056/NEJMoa1814213 - DOI - PubMed